Fecha de actualización: marzo de 2021   

 

Discovery
Click for more info Project Teaser


 Indication
 Target
CM-272 Cancer
Research Group		 DNMT & G9a

 
CM-1315 Onco-immunology

Research Group

 Disruption of FOXP3 dimerization

 
Apo-Insulin

Diabetes

Research Group

 Insulin
Receptor

 
Sushi-IL15-
Apo		 Onco-immunology
Research Group		 Receptor
IL-15

 
Apo-
FGF19		 Liver
regeneration
Research Group		 FGF19 receptor

 
Target ID In vitro
Assays		 Hit ID In vivo PoC
/ Lead id 		ADMET / PK
Optimización 		Preclinical Clinical
 
   
     
     
     
IP
ok
ok
ok
ok
ok
 


 

Early Discovery
Click for more info Project Teaser


 Indication
 Target
Viro Therapy Onco-immunology
Research Group

Inmune response

 
Eliratra Onco-immunology

Research Group

 Immune response

 
CM-1351 Onco-immunologyResearch Group

 Disruption Foxp3/ NFAT interaction

 
CM-3132 Dravet Syndrome
Research Group		 SCN1A

 
Target ID In vitro
Assays		 Hit ID In vivo PoC
/ Lead id 		ADMET / PK
Optimización
 
 
 
Partners
 IP
   
   
Undisclosed in-process
  in-process
 


 

Licensed Products in PreClinical & Clinical Phases
Click for more info Project Teaser


 Indication
CardioPatch Heart Failure

Research Group
EDA vaccine Cervical
Cancer

Research Group
CM-1349 Acute
intermittent porphyria

Research Group
a5-IFN Manufacturing
rh-CT 1 * Acute kidney injure
AAV-PBGD * Acute intermittent Porphyria
CM-144 * Scleroderma
AAV-GBA GT for CNS
C4 activation fragment Lung Cancer

Research Group
R&D Preclinical
Phase I Phase II Phase III
     
     
     
 
 
 
 
     
     
Licensed
 IP
Viscofan ok
Formune ok
Moderna Therapeutics ok
BioTechpharma ok
Bita ok
Uniqure ok
Bita ok
Handl therapeutics ok
Amadix ok

 

* Terminated